Generic IV Chemotherapy — 18-drug billing & coding rollup

Category overview — long-tail generic IV chemo in 2026 Reviewed May 2026

Why a rollup: shared admin code infrastructure, shared NCCN PA logic, but per-drug HCPCS and per-drug NDC-driven modifier rules.

The long-tail generic IV chemotherapy market is the quiet workhorse of medical-oncology billing. Cyclophosphamide (the "C" in CHOP / R-CHOP), 5-fluorouracil (the spine of every FOLFOX / FOLFIRI infusion), cytarabine and daunorubicin or idarubicin (the 7+3 AML induction), doxorubicin / cyclophosphamide (AC for breast), and the ABVD components for Hodgkin lymphoma are all old, off-patent, low-ASP commodities. They do not generate the per-page SEO volume of a Keytruda or an Enhertu, but they ride on every oncology claim and they share a characteristic billing pattern: low per-mg ASP, multi-dose vial presentations that scramble the JW / JZ modifier story, NCCN-driven payer policy with auto-approval for Category 1 / 2A regimens, foundation-only patient assistance (no manufacturer copay cards because the drugs are commodity generics), and high-volume claim throughput where small per-line errors compound into material AR.

The regimen landscape is what justifies grouping these drugs on one page. Hematologic malignancies depend on cyclophosphamide (CHOP, R-CHOP, hyper-CVAD, BEAM conditioning), cytarabine (7+3, HiDAC consolidation, R-DHAP / R-ICE salvage), conventional anthracyclines (daunorubicin or idarubicin in 7+3, mitoxantrone in relapsed AML or BV-AVD-historical), bleomycin (the "B" in ABVD), vincristine (CHOP, hyper-CVAD, R-CHOP-21), and methotrexate (HD-MTX for CNS lymphoma, intrathecal protocols). Solid tumors depend on 5-fluorouracil (the colon / rectal / pancreatic / gastric / head-and-neck backbone, including the 46-hour CIVI in FOLFOX / FOLFIRI / FOLFIRINOX), epirubicin (EC for breast in some pathways), and the older alkylators (dacarbazine in metastatic melanoma historical, ifosfamide + mesna in sarcoma and germ-cell, mitomycin in Nigro for anal squamous-cell). Hormone-sensitive malignancies use goserelin (prostate ADT, breast hormone deprivation, fertility preservation).

For revenue cycle, the failure modes cluster in four places. First, JW / JZ modifier errors on multi-dose vial lines (5-FU MDV, methotrexate MDV, bleomycin, certain mitomycin presentations) — the JW / JZ exclusion is one of the highest-volume audit findings on chemo claims. Second, 96416 vs 96417 confusion on portable-pump 5-FU CIVI — 96416 is the correct code for the pump setup, 96417 is the same-day additional-drug add-on for sequential drugs and is a frequent miscode. Third, missing the mesna line on ifosfamide claims — mesna is the FDA-required uroprotectant and bills on a separate line; coders who forget it leave revenue on the table and produce an incomplete claim record. Fourth, NCCN-compliance documentation — major payers now auto-approve Category 1 / 2A regimens with the regimen citation, but Category 2B and off-label use need biomarker / molecular / case-by-case documentation. This page maps each of those touchpoints.

Cross-links to dedicated drug pages — not on this rollup Reviewed May 2026

If you came here looking for one of these, you want the dedicated page. We cross-link to avoid duplicating coverage.

Per-drug regimen & dosing matrix Reviewed May 2026

Standard dosing per the most-cited regimen for each agent. Verify against NCCN, institutional protocol, and the FDA label for the specific indication.

NDC & manufacturer reference Reviewed May 2026

Representative NDCs for the most-billed presentations. These are commodity generics with many manufacturers — the table is illustrative; verify the dispensed NDC per claim.

Administration codes — 96413, 96415, 96416 vs 96417, 96409, 96402 Reviewed May 2026

The chemo administration ladder; the 46-hour CIVI 5-FU pump rule; and the goserelin SC hormonal exception.

The 46-hour CIVI 5-FU pump — mapped carefully

Modifiers — JW / JZ with the multi-dose vial exclusion Reviewed May 2026

CMS CR 12056 is the source of truth. SDV / single-use packaging only.

Per CMS Change Request 12056 (JZ mandatory effective July 1, 2023), the JW (drug discarded) and JZ (no discarded amount) modifiers apply only to single-dose containers (SDV) and single-use packaging. Multi-dose vial (MDV) presentations are excluded because the leftover drug is preserved for subsequent doses — nothing is discarded at the patient level. Several agents on this rollup have common MDV presentations and require the modifier-exclusion logic:

Other modifiers seen on chemo claims

• 59 / X{E,S,P,U} — distinct procedural service; used when admin code pairs would otherwise be bundled (e.g., 96413 with 96365 on the same day for a non-chemo hydration).
• 25 — significant separately identifiable E/M on the same day as the chemo administration; applied to the office visit, not the drug or admin line.
• SY / TH / GA — payer-specific modifiers; verify per-payer LCD / commercial policy.
• GA — ABN on file (Medicare); occasionally used on off-label or non-NCCN-compliant chemo lines as a defensive measure.

ICD-10 anchors by regimen / cancer Reviewed May 2026

Every chemo line needs Z51.11 (encounter for antineoplastic chemo) plus the malignancy code.

Every chemo administration line should also pair with Z51.11 (encounter for antineoplastic chemotherapy) as either primary or secondary diagnosis. Documentation should support the cancer ICD-10 with pathology / staging / biomarker as appropriate. NCCN-compliant regimens auto-approve at most major commercial payers; non-NCCN-compliant or Category 2B regimens need additional documentation in the chart and the PA submission.

Site of care — HOPD vs freestanding vs oncology office vs home Reviewed May 2026

Most generic IV chemo is given in HOPD (POS 22), freestanding infusion (POS 49), or oncology office (POS 11). The 46-hour CIVI 5-FU pump goes home with the patient.

• HOPD (POS 22) — hospital outpatient infusion suite; most-common setting for in-suite chemo (96413 + 96415 + 96416 / 96417 ladder). OPPS-paid; ASP+6% drug payment.
• Freestanding ambulatory infusion (POS 49) — same coding structure; PFS-paid; the high-volume site for FOLFOX / FOLFIRI in community oncology.
• Oncology office (POS 11) — physician office buy-and-bill; same admin codes; sequestration cuts (currently 1% effective Part B cut) apply on the drug payment.
• Home (POS 12) — for the 46-hour CIVI 5-FU pump after initiation in suite, the patient wears the pump home. The pump removal at return visit is bundled into the global 96416 service per CMS.
• Inpatient (POS 21) — 7+3 AML induction is typically inpatient; the chemo cost is bundled into the DRG payment, not separately billed. Daunorubicin / idarubicin / cytarabine on inpatient claims do NOT carry separate J-code reimbursement.
• SNF (POS 31 / 32) — rare for buy-and-bill chemo; if administered in an SNF Part A stay, the chemo is bundled in the SNF PPS rate. Outside Part A consolidated billing, drug J-code may be separately payable.

HOPD vs freestanding payment differential

For commodity generic chemo with low per-mg ASP, the OPPS (HOPD) vs PFS (freestanding) drug payment differential is largely the admin-code packaging logic, not the drug. Both pay drug at ASP+6% (minus sequestration). The admin code packaging in OPPS is generally separately payable at OPPS-specific rates; PFS pays at PFS facility / non-facility rates. For high-volume community oncology, freestanding AIC is typically the lowest-cost site for the payer and the highest-margin site for the practice; HOPD adds facility-fee uplift but is increasingly under site-neutral payment pressure.

Claim form fields — CMS-1500 example Reviewed May 2026

Example for a single-day FOLFOX cycle (5-FU bolus + leucovorin push + oxaliplatin infusion + 46-hr 5-FU CIVI pump).

Place of service: 22 (HOPD), 49 (freestanding AIC), or 11 (office). Rendering provider NPI / billing practitioner NPI on each line. ICD-10 in Block 21 with the cancer code (C18.x) and Z51.11 referenced via the diagnosis pointer in Block 24E.

Payer policies — NCCN compliance is the unifying gate Reviewed May 2026

UHC, Aetna, BCBS, Cigna, and Humana auto-approve NCCN Category 1 / 2A regimens. Category 2B and off-label need biomarker / molecular / case rationale.

NCCN Category levels — what they mean for PA

• Category 1 — high-level evidence + uniform NCCN consensus. Auto-approves at most major payers.
• Category 2A — lower-level evidence but uniform consensus. Auto-approves at most major payers.
• Category 2B — lower-level evidence with some consensus disagreement. Often requires additional documentation; biomarker / molecular / case-by-case support strengthens the PA.
• Category 3 — major disagreement on appropriateness. Rarely seen; usually requires medical-director peer-to-peer.

Medicare reimbursement — Q2 2026 ASP per code Reviewed May 2026

CMS Part B Drug ASP Pricing File, Q2 2026. ASP+6% (with sequestration adjustment) is the buy-and-bill payment.

Why so many codes have low ASP

Most agents on this rollup are decades-old commodity generics with many manufacturers competing on per-mg acquisition cost. ASP+6% on a per-mg basis is often less than $5 per administered dose — the revenue model for these drugs is volume across many cycles, not per-cycle margin. The high-cost outliers on this page are idarubicin (J9211, $39.756 per 5 mg), mitoxantrone (J9293, $38.614 per 5 mg), mitomycin (J9280, $28.459 per 5 mg), ifosfamide (J9208, $24.682 per 1 g), bleomycin (J9040, $16.598 per 15 units), and goserelin (J9202, $777.502 per 3.6 mg implant — an outlier because it's a depot device, not commodity injectable).

Patient assistance — foundations only Reviewed May 2026

Commodity generics don't have manufacturer copay cards. Foundation PAP (CancerCare, PAN, HealthWell, LLS, BMS Foundation) is the source of patient assistance.

Because the agents on this rollup are commodity generics with stable, low ASP, the originator manufacturers long ago discontinued any branded patient-assistance programs — there are no Cytoxan, Adriamycin, or Cosmegen copay cards in 2026. The patient-assistance pathway is foundation-based, indication-driven (not drug-driven), and works the same way across most of the rollup:

Workflow for assistance enrollment

• Patient income and insurance verification (most foundations require ≤ 400–500% FPL).
• Diagnosis confirmation (pathology or clinic note with ICD-10).
• Insurance EOB or claim showing the copay obligation (some foundations require this; others enroll first).
• Foundation portal enrollment; approval typically within 24–48 hours when funds are open.
• Reauthorization annually or per fund cycle.

Top denials — the six recurring patterns Reviewed May 2026

Each row is a recurring denial pattern, the root cause, and the fix-and-resubmit workflow.

FAQ Reviewed May 2026

Twelve recurring questions from billers / coders working long-tail generic chemo claims.

Which IV chemo drugs are on this rollup vs a dedicated page?

This rollup covers the long-tail generic IV chemotherapy agents that do not have their own dedicated CareCost page: cyclophosphamide (J9070), ifosfamide (J9208) with mesna (J9209), dacarbazine (J9130), daunorubicin (J9151), idarubicin (J9211), epirubicin (J9178), mitoxantrone (J9293), 5-fluorouracil (J9190), methotrexate IV (J9250 / J9260), cytarabine (J9100), leucovorin (J0640), vinblastine (J9360), vincristine (J9370), goserelin (J9202), mitomycin (J9280), and bleomycin (J9040). Drugs with their own dedicated CareCost pages are: carboplatin (J9045), cisplatin (J9060), oxaliplatin (J9263), irinotecan (J9206), paclitaxel (J9267), Abraxane / nab-paclitaxel (J9264), Doxil / Lipodox (Q2050), doxorubicin conventional (J9000), gemcitabine (J9201), pemetrexed (J9305), Bendeka / bendamustine (J9034), and Onivyde liposomal irinotecan (J9205).

Why is JW / JZ excluded for multi-dose vial chemo drugs?

Per CMS Change Request 12056 (effective July 1, 2023 for JZ, with JW longstanding), the JW (drug discarded) and JZ (no discarded amount) modifiers apply only to single-dose containers (SDV) and single-use packages. Multi-dose vials (MDV) are excluded from both modifiers because the leftover drug is preserved for subsequent doses, not discarded. Several agents on this page are commonly available in MDV presentations — 5-fluorouracil (50 mg/mL MDV in 500 mg / 1 g / 2.5 g / 5 g sizes), methotrexate sodium (25 mg/mL MDV), bleomycin (15 unit MDV), and mesna (1 g / 10 mL MDV at 100 mg/mL). Coders must verify the dispensed NDC against the FDA presentation: if MDV, no JW / JZ; if SDV, JZ when fully used, JW + a separate waste line when discarded.

How do I bill 46-hour continuous-infusion 5-FU?

Continuous-infusion 5-FU (CIVI) over 46 hours is the backbone of FOLFOX, FOLFIRI, and FOLFIRINOX regimens for colorectal and pancreatic cancer. Standard delivery is via a portable elastomeric infusion pump (e.g., Baxter Intermate / Easypump / Eclipse) that the patient wears home and returns at the end of the infusion. The drug J-code stays J9190 (5-fluorouracil, per 500 mg) and units reflect the total mg delivered. The administration code is 96416 (chemotherapy administration, IV infusion, requiring use of portable or implantable pump) for the prolonged-infusion setup — NOT 96417, which is the same-day additional-drug add-on for sequential drugs. The 96416 code is reported once per encounter regardless of pump duration.

When do I bill mesna alongside ifosfamide?

Mesna (Mesnex, J9209, per 200 mg) is the uroprotectant required to prevent hemorrhagic cystitis from ifosfamide (J9208) and high-dose cyclophosphamide. The standard dosing ratio is mesna at 60% of the ifosfamide dose split across three doses (start / +4h / +8h). Mesna and ifosfamide are billed on separate claim lines with their own J-codes — they are not bundled. Both lines need the appropriate cancer ICD-10 anchor. Mesna without ifosfamide (or documented high-dose cyclophosphamide) will be denied as not medically necessary.

What's the difference between daunorubicin (J9151) and idarubicin (J9211)?

Both are anthracycline IV chemotherapy agents primarily used in acute myeloid leukemia (AML) induction (the "7+3" cytarabine-anthracycline backbone). Daunorubicin (Cerubidine, J9151, per 10 mg) is the original conventional formulation dosed at 60–90 mg/m² IV daily × 3 days as part of 7+3. Idarubicin (Idamycin PFS, J9211, per 5 mg) is a more lipophilic analog dosed at 12 mg/m² IV daily × 3 days. Both have similar cardiotoxicity profiles. Note: liposomal daunorubicin-cytarabine (Vyxeos, J9153) is a separate fixed-ratio product and is NOT on this rollup.

Cytarabine high-dose (HiDAC) vs standard dose — same J-code?

Yes — cytarabine is always J9100 (Cytosar-U / Ara-C, per 100 mg) regardless of dose. Standard-dose cytarabine is 100–200 mg/m²/day continuous infusion × 7 days in the 7+3 AML induction backbone. High-dose cytarabine (HiDAC) is 1–3 g/m² every 12 hours × 6–12 doses, typically as consolidation in AML, lymphoma salvage, or CNS prophylaxis. Units billed scale with mg delivered; the J-code does not change. Liposomal cytarabine (DepoCyt, intrathecal) is a separate product with HCPCS J9098 and is not on this rollup.

Vincristine — NEVER intrathecal warning impact on billing?

Vincristine (J9370, per 1 mg) carries an FDA-mandated boxed warning that it is FATAL if administered intrathecally and is for IV use only. From a billing standpoint, every vincristine dispense should be in a syringe labeled "FOR INTRAVENOUS USE ONLY," and pharmacy SOPs require dispense in a minibag (50 mL) rather than syringe in many institutions per the 2018 ISMP / ASHP / ASCO joint recommendations. The administration code is 96409 (IV push) for the traditional push delivery, or 96413 if given as a minibag infusion. Route documentation must specifically state intravenous. Vincristine sulfate liposome (Marqibo, J9371) is a separate product, not on this rollup.

Leucovorin vs levoleucovorin — same drug?

No — two distinct products. Leucovorin calcium (folinic acid, J0640, per 50 mg) is the racemic dl-leucovorin used as methotrexate rescue and 5-FU modulator. Levoleucovorin (Fusilev / Khapzory, J0641, per 0.5 mg) is the pharmacologically active l-isomer alone, half the dose. Verify the dispensed NDC. Mixing them up on the claim produces immediate denials.

Goserelin (Zoladex) on a chemo rollup — why?

Goserelin (J9202, per 3.6 mg) is an LHRH agonist, not a cytotoxic chemotherapy, but it lives on this rollup because it is administered as a deep SC depot implant in oncology offices on the same chemo billing infrastructure for prostate cancer (C61) and breast cancer (C50.x) hormone-deprivation indications. The 10.8 mg three-month depot is also J9202 (units reflect mg). Administration is via 96402 (chemo SC / IM hormonal anti-neoplastic). For Lupron see the dedicated lupron-depot page; for Firmagon (degarelix) see firmagon.

Mitomycin (J9280) — still used in 2026?

Yes — mitomycin remains in use for intravesical instillation in non-muscle-invasive bladder cancer (with companion thermochemotherapy or Jelmyto for upper-tract urothelial), as part of the Nigro regimen (mitomycin + 5-FU + concurrent radiation) for anal canal squamous cell carcinoma, and occasional use in cervical / pancreatic / gastric protocols. Cumulative-dose nephrotoxicity (mitomycin-HUS) is the recognized late toxicity. Pyelocalyceal mitomycin (Jelmyto) is a separate product and not on this rollup.

Bleomycin (J9040) cumulative dose tracking — billing implication?

Bleomycin (J9040, per 15 units) is the "B" in ABVD (Hodgkin) and a component of BEP (testicular germ-cell). The recognized cumulative-dose pulmonary toxicity (bleomycin pneumonitis / interstitial fibrosis) typically emerges above 400 units total lifetime exposure. The billing implication is that the chart needs lifetime cumulative-dose tracking across treatment settings — a documented running total strengthens the medical-necessity record for continuing therapy at higher exposure.

What ICD-10 anchors does a generic chemo claim need?

Every chemotherapy administration line needs Z51.11 (encounter for antineoplastic chemotherapy) as either primary or secondary, paired with the malignancy ICD-10. Common anchors: C50.x (breast for AC, EC), C61 (prostate for goserelin), C18.x / C19 / C20 (CRC for FOLFOX / FOLFIRI), C25.x (pancreas for FOLFIRINOX), C92.0 (AML for 7+3 with cytarabine + daunorubicin / idarubicin), C81.x (Hodgkin for ABVD / BEACOPP), C83.x / C85.x (NHL / DLBCL for CHOP / R-CHOP), C21.x (anal canal for Nigro mitomycin), C67.x (bladder for intravesical mitomycin), C62.x (testicular for BEP bleomycin). Document the NCCN regimen citation in the chart.

Source documents

Primary sources cited inline above. This list is for verification audit.

• NCCN Clinical Practice Guidelines in Oncology (B-Cell Lymphomas, Hodgkin Lymphoma, AML, Breast, Colon, Rectal, Pancreatic, Testicular, Bladder, Anal, Soft Tissue Sarcoma, Bone Sarcoma) — nccn.org/guidelines. Cancer-type-specific regimen recommendations and category levels used for payer auto-approval logic.
• FDA Prescribing Information (current labels) for cyclophosphamide, ifosfamide (Ifex), mesna (Mesnex), dacarbazine, daunorubicin (Cerubidine), idarubicin (Idamycin PFS), epirubicin (Ellence), mitoxantrone, 5-fluorouracil, methotrexate sodium, cytarabine, leucovorin calcium, vinblastine, vincristine, goserelin (Zoladex), mitomycin, and bleomycin sulfate — FDA Drugs@FDA. Dosing, route, boxed warnings (vincristine, bleomycin pulmonary, anthracycline cardiotoxicity, etc.), and approved indications.
• CMS Change Request 12056 — JW / JZ modifier policy effective July 1, 2023; multi-dose vial exclusion language. CMS R12056. Authoritative source for the MDV JW / JZ exclusion logic.
• CMS Part B Drug ASP Pricing File (Q2 2026) — cms.gov ASP pricing files. Source of truth for ASP+6% per-HCPCS payment.
• CMS MLN Booklets — "Discarded Drugs and Biologicals (JW and JZ Modifiers)" MLN MM12667; chemotherapy administration coding MLN guidance. CMS MLN catalog.
• AMA CPT® Codebook 2026 — chemotherapy administration code section (96401–96549). ama-assn.org/practice-management/cpt. Authoritative source for 96409 / 96411 / 96413 / 96415 / 96416 / 96417 / 96401 / 96402 descriptors.
• ISMP / ASHP / ASCO 2018 vincristine minibag safety recommendations — standardization of vincristine dispense in minibag rather than syringe to prevent intrathecal misadministration. ismp.org.
• ASCO / ONS Chemotherapy Administration Safety Standards (2016 update) — institutional policy framework. asco.org/practice-policy.
• Foundation patient assistance directories — CancerCare, PAN Foundation, HealthWell, LLS, BMS Foundation / PAN, Good Days, Patient Advocate Foundation. URLs in the patient-assistance section above.
• NDC Directory (FDA) — FDA NDC Directory. Verification of dispensed NDC presentations and SDV / MDV classification.

About this page

We maintain this rollup as a living reference for billers and coders working long-tail generic IV chemotherapy claims. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Why a rollup? Per-drug standalone pages for every long-tail generic chemo agent produce lower per-page SEO value than category-level reference pages with clear per-drug subsections. The rollup format also matches how billers actually work the claim — a CHOP or AC or FOLFOX cycle covers multiple drugs in one encounter, not one drug at a time.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 22, 2026 — Initial publication. 18 long-tail generic IV chemotherapy agents across alkylators (cyclophosphamide, ifosfamide, dacarbazine) + uroprotectant (mesna) + conventional anthracyclines (daunorubicin, idarubicin, epirubicin, mitoxantrone) + antimetabolites (5-FU, methotrexate, cytarabine, leucovorin) + vinca alkaloids (vinblastine, vincristine) + LHRH agonist (goserelin) + antitumor antibiotics (mitomycin, bleomycin). ASP data: Q2 2026 where current-quarter CMS entries exist; J9070 / J9151 / J9250 have no current entry and bill at acquisition + handling. Wave 8 commodity rollup format.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File where a current-quarter entry exists; codes without current-quarter entries (J9070 cyclophosphamide, J9151 daunorubicin, J9250 methotrexate 5 mg, J9202 goserelin Q1-fallback) are flagged. Payer policies are read directly from each payer's published medical / pharmacy policy documents. Indication lists, dosing, boxed-warning content, and cumulative-dose tracking are verified against the current FDA label revision and the relevant NCCN guideline. We do not paraphrase from billing-software vendor blogs.